Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Aug 1.

Published in final edited form as: J Alzheimers Dis. 2012;29(3):691–697. doi: 10.3233/JAD-2012-110629

Fig. 1 — Docosahexaenoic acid (DHA) in plasma total lipids (TL), triglycerides (TG), cholesteryl esters (CE), free fatty acids (FFA) and phospholipids (PL) expressed as % composition (upper panel) or concentration (mg/dL; lower panel). Bars are for no cognitive impairment (■, n = 10), mild cognitive impairment (□, n = 7), or Alzheimer’s disease ( , n = 9). Data for Alzheimer’s disease were significantly different from the no cognitive impairment group and/or the mild cognitive impairment group (*p < 0.05; Kruskal-Wallis followed by Mann-Whitney tests).

Inline graphic — Docosahexaenoic acid (DHA) in plasma total lipids (TL), triglycerides (TG), cholesteryl esters (CE), free fatty acids (FFA) and phospholipids (PL) expressed as % composition (upper panel) or concentration (mg/dL; lower panel). Bars are for no cognitive impairment (■, n = 10), mild cognitive impairment (□, n = 7), or Alzheimer’s disease ( , n = 9). Data for Alzheimer’s disease were significantly different from the no cognitive impairment group and/or the mild cognitive impairment group (*p < 0.05; Kruskal-Wallis followed by Mann-Whitney tests).